Nanotechnology's frontier in combatting infectious and inflammatory diseases: prevention and treatment

Y Huang, X Guo, Y Wu, X Chen, L Feng, N **e… - … and Targeted Therapy, 2024‏ - nature.com
Inflammation-associated diseases encompass a range of infectious diseases and non-
infectious inflammatory diseases, which continuously pose one of the most serious threats to …

Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models

AA Cohen, N van Doremalen, AJ Greaney, H Andersen… - Science, 2022‏ - science.org
To combat future severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
and spillovers of SARS-like betacoronaviruses (sarbecoviruses) threatening global health …

Nanoparticle display of prefusion coronavirus spike elicits S1-focused cross-reactive antibody response against diverse coronavirus subgenera

GB Hutchinson, OM Abiona, CT Ziwawo… - Nature …, 2023‏ - nature.com
Multivalent antigen display is a fast-growing area of interest toward broadly protective
vaccines. Current nanoparticle-based vaccine candidates demonstrate the ability to confer …

An optimized messenger RNA vaccine candidate protects non-human primates from Zika virus infection

B Bollman, N Nunna, K Bahl, CJ Hsiao, H Bennett… - npj Vaccines, 2023‏ - nature.com
Zika virus (ZIKV), an arbovirus transmitted by mosquitoes, was identified as a cause of
congenital disease during a major outbreak in the Americas in 2016. Vaccine design …

Immunogenicity and protection of a variant nanoparticle vaccine that confers broad neutralization against SARS-CoV-2 variants

J Logue, RM Johnson, N Patel, B Zhou… - Nature …, 2023‏ - nature.com
SARS-CoV-2 variants have emerged with elevated transmission and a higher risk of
infection for vaccinated individuals. We demonstrate that a recombinant prefusion-stabilized …

Potent neutralization of SARS-CoV-2 variants by RBD nanoparticle and prefusion-stabilized spike immunogens

MC Miranda, E Kepl, MJ Navarro, C Chen, M Johnson… - npj Vaccines, 2024‏ - nature.com
We previously described a two-component protein nanoparticle vaccine platform that
displays 60 copies of the SARS-CoV-2 spike protein RBD (RBD-NP). The vaccine, when …

Immunogenicity and efficacy of a novel multi-patch SARS-CoV-2/COVID-19 vaccine candidate

B Perdiguero, L Marcos-Villar, M López-Bravo… - Frontiers in …, 2023‏ - frontiersin.org
Introduction While there has been considerable progress in the development of vaccines
against SARS-CoV-2, largely based on the S (spike) protein of the virus, less progress has …

Different configurations of SARS-CoV-2 spike protein delivered by integrase-defective lentiviral vectors induce persistent functional immune responses, characterized …

M Borghi, A Gallinaro, MF Pirillo, A Canitano… - Frontiers in …, 2023‏ - frontiersin.org
Several COVID-19 vaccine strategies utilizing new formulations for the induction of
neutralizing antibodies (nAbs) and T cell immunity are still under evaluation in preclinical …

Mosaic RBD nanoparticles protect against multiple sarbecovirus challenges in animal models

AA Cohen, N van Doremalen, AJ Greaney… - …, 2022‏ - pmc.ncbi.nlm.nih.gov
To combat future SARS-CoV-2 variants and spillovers of SARS-like betacoronaviruses
(sarbecoviruses) threatening global health, we designed mosaic nanoparticles presenting …

Preclinical immunogenicity and protective efficacy of a SARS-CoV-2 RBD-based vaccine produced with the thermophilic filamentous fungal expression system …

M Gonzalez-Hernandez, FK Kaiser, I Steffen… - Frontiers in …, 2023‏ - frontiersin.org
Introduction The emergency use of vaccines has been the most efficient way to control the
coronavirus disease 19 (COVID-19) pandemic. However, the emergence of severe acute …